伊特拉可纳在人类医学和兽医实践中的应用
Yamara V Sousa1, Marie G Santiago1, Bianca M de Souza2
1Department of Pharmaceuticals, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Av Antônio Carlos, 6627, Belo Horizonte, MG 31270-901, Brazil.
Journal de mycologie medicale
|March 17, 2024
概括
伊特拉科纳 (ITZ) 是一种广泛用于人类和兽医的抗真菌药物,有效对抗各种真菌感染. 本综述详细介绍了ITZ的使用,剂量和人类和动物患者的临床考虑.
科学领域:
- 兽医医学 兽医医学 兽医医学
- 人类医学 人类医学 医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 真菌感染对人类和动物的健康构成挑战,特别是在免疫受损的个体中.
- 伊特拉科纳 (ITZ) 是一种具有良好的安全性特征的广谱抗真菌药物,是治疗和预防的常见选择.
- 人类和兽医真菌感染之间日益增长的关联凸显了对比治疗见解的需求.
研究的目的:
- 审查伊特拉科纳 (ITZ) 在人类和兽医学中的临床应用.
- 讨论影响ITZ剂量和治疗持续时间的因素.
- 整合关于ITZ使用的信息,包括病例报告和临床方面,对于人类和动物的健康.
主要方法:
- 科学文章和案例报告的文献综述.
- 在人类和兽医临床环境中分析伊特拉科纳的使用模式.
- 综合了关于ITZ的剂量,疗效和安全性的数据.
主要成果:
- 伊特拉科纳是一种经常被处方的抗真菌药物,用于广泛的真菌感染.
- 根据物种,感染地点,病原体敏感性和宿主因素,ITZ的剂量有很大差异.
- 人类剂量通常在100-400毫克/天之间,而兽医剂量在3-50毫克/公斤/天之间.
结论:
- 伊特拉可纳是一种有价值的治疗剂,用于管理人类和兽医的真菌感染.
- 了解特定物种的剂量和临床细微差别对于优化ITZ治疗至关重要.
- 本综述为临床医生管理人类和动物患者ITZ的真菌感染提供了全面的资源.
相关概念视频
01:13Therapeutic Index
4.2K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
4.2K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
118
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
118
01:11Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K